Fluvoxamine Augmentation Increases Serum Mirtazapine Concentrations Three- to Fourfold

@article{Anttila2001FluvoxamineAI,
  title={Fluvoxamine Augmentation Increases Serum Mirtazapine Concentrations Three- to Fourfold},
  author={S. Anttila and I. Rasanen and E. Leinonen},
  journal={Annals of Pharmacotherapy},
  year={2001},
  volume={35},
  pages={1221 - 1223}
}
OBJECTIVE: To report two cases of interaction between fluvoxamine and mirtazapine. CASE SUMMARY: A 17-year-old boy was treated with mirtazapine 30 mg/d. The addition of fluvoxamine 100 mg/d to the regimen caused a threefold increase in the mirtazapine concentration. This interaction was associated with increased anxiety. A second patient, a 43-year-old woman, was treated with mirtazapine 15 mg/d. There was a fourfold increase in her mirtazapine concentration and simultaneous mood improvements… Expand
Population pharmacokinetic analysis of mirtazapine
TLDR
The variability of mirtazapine plasma concentrations in clinical routine is caused to a relevant degree by CYP2D6, and should be taken into account when therapeutic drug monitoring is carried out to check treatment adherence or when a special clinical situation demands careful dosing of this drug. Expand
PHARMACOKINETICS A ND D ISPOSITION
TLDR
The variability of mirtazapine plasma concentrations in clinical routine is caused to a relevant degree by CYP2D6, and should be taken into account when therapeutic drug monitoring is carried out to check treatment adherence or when a special clinical situation, such as co-morbidity and add-on medication, demands careful dosing of this drug. Expand
Mirtazapine: a review of its use in major depression and other psychiatric disorders.
TLDR
Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders, obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed. Expand
Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
TLDR
Findings prove the inhibitory effects of ecstasy on both CYP2D6 and CYP3A4 hepatic isoenzymes on both MRZ andMDMA in liver. Expand
Metabolic drug interactions with new psychotropic agents
TLDR
The potential for metabolically based drug interactions of any new psychotropic agent may be anticipated on the basis of knowledge about the CYP enzymes responsible for its metabolism and about its effect on the activity of these enzymes. Expand
Comment: Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine
TLDR
The clinical features and time course of the condition reported by Benazzi are more consistent with selective serotonin-reuptake inhibitor (SSRI) withdrawal, in this case, the cessation of fluoxetine. Expand
Delirium Associated with Mirtazapine Substituting Duloxetine in a Depressed Patient with Alzheimer’s Dementia
Depression is a common and important comorbidity in dementia, so antidepressants are frequently used for treating depression in dementia [1]. Limited evidence suggests that for certain elderlyExpand
Clinically Significant Drug Interactions with Newer Antidepressants
TLDR
Although drug interactions with newer antidepressants are potentially, but rarely, clinically significant, the use of antidepressants with a more favourable drug interaction profile is advisable. Expand
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
TLDR
Second-generation antidepressants are not equivalent in their potential for pharmacokinetic drug interactions and, although interactions may be predictable in specific circumstances, use of an antidepressant with a more favorable drug-interaction profile may be justified. Expand
Mirtazapine in the treatment of mood and anxiety disorders
Mirtazapine is a new antidepressant whose effects on presynaptic adrenergic receptors leads to increased serotonergic transmission, and thus its antidepressant and antianxiety effects. It is equal inExpand
...
1
2
3
...

References

SHOWING 1-10 OF 13 REFERENCES
Concomitant use of mirtazapine and cimetidine: a drug–drug interaction study in healthy male subjects
TLDR
Co-administration of cimetidine and mirtazapine resulted in increased steady-state plasma levels of mirtzapine, probably as a result of increased bio-availability, and the clinical meaning of these increases is probably limited. Expand
Clinical Pharmacokinetics of Mirtazapine
TLDR
Mirtazapine is the first noradrenergic and specific serotonergic antidepressant (‘NaSSA’) and appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(−)-enantiomer compared with that of the(S)-(+)- enantiomer (9.9±3.1h). Expand
Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
TLDR
Fluvoxamine markedly interferes with the metabolism of THD, probably at the CYP2C19 and/or CYP1A2 enzyme level, and clinicians should be aware of the potential for a clinical drug interaction between both compounds, and careful monitoring ofTHD levels is valuable to prevent the accumulation of the drug and resulting toxicity. Expand
Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin
TLDR
The serum MT level increased markedly after ingestion of FLU but not after CIT, and decreased hepatic metabolism of MT by either CYP1A2 or CYP2C19, or both, is probable. Expand
A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
TLDR
All of the calculated steady-state pharmacokinetic parameter changes for baclofen, tizanidine, and its major metabolites were within the 30% criterion, meaning it is unlikely that coadministration of tIZanidine and bacl ofen during dose-titration of the former will result in a pharmacokinetics interaction. Expand
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression
TLDR
Mirtazapine has been termed a noradrenergic and specific serotonergic antidepressant (NaSSA) and Reboxetine is the first selective Noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediateSerotonergic effects. Expand
Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
TLDR
Tizanidine is an antispastic agent with similar efficacy to that of baclofen and a more favourable tolerability profile and, while drowsiness is a frequently reported adverse effect with both agents, subjective muscle weakness appears to be less of a problem with tIZanidine than with bacl ofen. Expand
Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain
TLDR
It is suggested that mirtazapine may have a faster onset of action than a SSRI, and that the co-administration of mirtzapine and paroxetine may accelerate the antidepressant response and as well as being more effective than either drug alone. Expand
Review Nimesulide: Some Pharmaceutical and Pharmacological Aspects—An Update
TLDR
Initial general clinical experience with selective COX‐2 inhibitors appears to show that they are particularly promising in individuals at risk because of renal diseases, hypertension or congestive heart failure. Expand
Phenytoin-Tizanidine Interaction
TLDR
Toleranceto intravenous nitroglycerin in patients with congestiveheart failure: role of increasedravascular volume, neurohumoral activation and lack of prevention withN-acetylcysteine. Expand
...
1
2
...